Resolution Therapeutics
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Inflammation
Pioneering Regenerative Macrophage Therapy in Inflammatory and Fibrotic Diseases
UNMET MEDICAL NEED
First indication in End Stage Liver Disease (ESLD), currently in the clinic
TRANSFORMATIVE TREATMENT
Engineered macrophages with enhanced anti-inflammatory and anti-fibrotic efficacy
ROBUST SCIENCE & CLINICAL EVIDENCE
Two clinical proof of concept studies demonstrating safety and efficacy in patients with cirrhosis
FOCUSED PIPELINE
Efficacy demonstrated in lung fibrosis and GvHD with platform expansion into In Vivo modality
Company HQ City:
London
Company HQ State:
United Kingdom
Company HQ Country:
United Kingdom
Year Founded:
2020
Lead Product in Development:
RTX001
CEO
Amir Hefni
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
Interim P2 readout
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}